A phase I study to evaluate the T-cell engager AMV564 alone and in combination with pembrolizumab in subjects with advanced solid tumors von Starodub, Alexander, Piha-Paul, Sarina Anne, Karim, Raghad, Ruegg, Curtis, Smith, Victoria, Chun, Patrick Youngwhan

Volltext

Results of a phase 1 dose-escalation study of AMV564, a novel T-cell engager, alone and in combination with pembrolizumab in patients with relapsed/refractory solid tumors von Mettu, Niharika B., Starodub, Alexander, Piha-Paul, Sarina Anne Anne, Abdul-Karim, Raghad Muhsin, Tinoco, Gabriel, Shafique, Michael Rahman, Smith, Victoria, Baccei, Christina, Chun, Patrick Youngwhan

Volltext

A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent ga... von Shah, Manish A., Metges, Jean-Philippe, Chun, Patrick Youngwhan, Smith, Victoria, Maltzman, Julia D., Wainberg, Zev A.

Volltext

Development of quality indicators for women at high risk for breast cancer von Shahrokni, Armin, Chun, Patrick Youngwhan, Naeim, Arash, O’Leary, Erin M., Petruse, Antonia, Keefer, Lisa Jo, Wenger, Neil

Volltext